--- title: "ZAWYA-PRESSR: CE‑Ventures backs USD 55mln Series A funding of US biotech pioneer, Think Bioscience" type: "News" locale: "en" url: "https://longbridge.com/en/news/273178679.md" description: "CE-Ventures has participated in a USD 55 million Series A funding round for Think Bioscience, a biotech company focused on drug discovery using synthetic biology. The funding, led by Regeneron Ventures and others, will support Think Bio's development of small molecule drugs targeting previously undruggable proteins, including a lead program for Noonan syndrome. CE-Ventures aims to back innovative biotech ventures and will host a biotech event in Dubai in 2026." datetime: "2026-01-21T05:42:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273178679.md) - [en](https://longbridge.com/en/news/273178679.md) - [zh-HK](https://longbridge.com/zh-HK/news/273178679.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273178679.md) | [繁體中文](https://longbridge.com/zh-HK/news/273178679.md) # ZAWYA-PRESSR: CE‑Ventures backs USD 55mln Series A funding of US biotech pioneer, Think Bioscience Investment reinforces CE‑Ventures’ strategy of supporting globally competitive, R&D‑led biotech ventures Category-leading synthetic biology‑driven drug discovery company supported by leading international venture capitalists **Sharjah, United Arab Emirates** – CE‑Ventures, the corporate venture capital platform of Crescent Enterprises, today announced its participation in the Series A funding round for Think Bioscience (“Think Bio”), a biotechnology company pioneering novel approaches to historically challenging drug targets. The oversubscribed USD 55 million round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors, with participation from CE‑Ventures, MBX Capital, T.A. Springer, and YK Bioventures, alongside returning investors AV8 Ventures, CU Innovations, and Buff Gold Ventures. The new capital will support the advancement of Think Bio’s internal pipeline of first‑in‑class small molecule programs and further development of its synthetic biology discovery platform. Think Bioscience uses synthetic biology to uncover previously hidden footholds on proteins (such as novel pockets) that enable medicinal chemists to design small molecule drugs against targets long considered “undruggable”. The company’s lead program focuses on mutants that cause Noonan syndrome, a genetic condition affecting approximately 1 in 2,500 births and associated with serious cardiac and lymphatic complications, short stature, cognitive impairment, and chronic pain. There are currently no approved therapies that directly address the underlying biology of Noonan syndrome. “Think Bioscience is building a differentiated platform at the frontier of synthetic biology and drug discovery, with the potential to expand what is pharmaceutically possible for patients with high unmet need,” said Tushar Singhvi, Deputy CEO and Head of Investments at Crescent Enterprises. “Our investment reflects strong conviction in Think Bio’s approach and the opportunity to build a leading biotech company that can benefit patients worldwide.” Dr. Jerome Fox, co-founder and CEO at Think Bioscience commented, “Our lead program has the potential to give a broad set of Noonan patients a normal life**.** We are grateful to our investors for supporting our vision to develop life-changing therapies for patients in need.” Despite notable advances in computational chemistry, many proteins across the human proteome remain out of reach for conventional drug discovery because they lack obvious binding pockets for small molecules. Think Bio’s synthetic biology platform applies high‑throughput functional surveys to reveal new pockets and mechanism‑relevant sites, enabling the development of small molecules with biochemical activities previously viewed as difficult – if not impossible – to achieve. The company has extended this approach to a diverse set of targets and developed a robust internal pipeline of therapeutic programs. “Think Bioscience is addressing one of drug discovery’s most critical bottlenecks by enabling small-molecule drugs against historically undruggable targets. Their Noonan syndrome program highlights the platform’s potential where no approved therapies exist,” said Dr. Damir Illich, Manager, Life Sciences at CE-Ventures, who will join the company’s board as an observer. The investment in Think Bioscience builds on CE‑Ventures’ strategy of backing visionary entrepreneurs and R&D‑led, asset‑light business models across sectors, including deep‑tech and biotech, with the potential to compete on a global stage. CE-Ventures will again be convening global experts, clinicians, innovators, investors and policymakers at **‘The Microbiome Revolution’** its flagship biotech event on 5 February 2026 in Dubai. This year’s symposium is focussed on ‘Unlocking the Gut–Brain Axis for the Future of Health’, and with the human microbiome market projected to grow 5x in 5 years to more than USD 4 million by 2030, the event is set to attract senior leaders across healthcare, life sciences, nutrition, and investment to strengthen collaboration across the full pipeline, from research and validation to deployment and impact. **About CE-Ventures** CE-Ventures is the corporate venture capital platform of Crescent Enterprises, and invests in transformative businesses across industries, including consumer, deep-tech and biotech. CE-Ventures back visionary entrepreneurs by providing capital, resources, and a global network to build and scale exceptional businesses that drive long-term value. www.crescententerprises.com/ce-ventures **About Crescent Enterprises** Crescent Enterprises is a multinational company based in the United Arab Emirates (UAE) with strategic investments across sectors. Established in 2007, the business comprises a diversified group of 57 subsidiaries, affiliates, and investments across 19 countries, and employs more than 1,600 people. The corporate structure has four platforms: CE‑Operates, CE‑Invests, CE‑Ventures, and CE‑Creates. The platforms span various business sectors, including ports, logistics, food and beverages, healthcare, life sciences, and business aviation. They also include business verticals, such as private equity, venture capital, and business incubation. Crescent Enterprises is a subsidiary of Crescent Group, a family-owned business shaping the MENA region’s economy for over 50 years. www.crescententerprises.com **About Think Bioscience** Think Bioscience is a biotechnology company developing small molecule drugs for historically challenging drug targets by combining synthetic biology with cutting‑edge medicinal chemistry. The company is headquartered in Boulder, Colorado, and is advancing a pipeline of first‑in‑class programs, including a lead asset targeting the genetic drivers of Noonan syndrome. www.thinkbioscience.com **For media inquiries please contact:** Charlie Scott, cscott@crescent.ae Ghyna Kurdy, g.kurdy@saharapr.com## Send us your press releases to pressrelease.zawya@lseg.com Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release. The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk. To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages. ### Related Stocks - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [Regeneron Pharmaceuticals, Inc. (REGN.US)](https://longbridge.com/en/quote/REGN.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) ## Related News & Research - [Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus](https://longbridge.com/en/news/281522861.md) - [Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout](https://longbridge.com/en/news/281635912.md) - [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md) - [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/en/news/281517197.md) - [Oculis' Privosegtor Granted Priority Medicines Designation in Europe for Optic Neuritis](https://longbridge.com/en/news/281158152.md)